Related Experiment Videos
[Medical therapy corresponding to the morbid state of hyperlipidemia]
1Department of Metabolic Medicine, Kumamoto National Hospital.
Insights
Statins reduce coronary artery disease and overall mortality by preventing cardiovascular events and improving plaque stability. Japanese clinical trials confirm these benefits, guiding hyperlipidemia management strategies.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Context:
- Statin therapy significantly reduces coronary artery disease (CAD) onset and mortality rates.
- Evidence from European and USA trials established statins' efficacy.
- A need existed for data specific to Japanese populations due to potential dosage and genetic differences.
Purpose:
- To evaluate the impact of statin use on cardiovascular outcomes in a Japanese population.
- To understand the role of statins in managing hyperlipidemia and atherosclerosis.
- To inform clinical practice regarding lipid-lowering agent mechanisms and patient-specific treatment.
Summary:
- Statin use led to decreased rates of coronary artery disease onset, mortality, and overall mortality.
- Mechanisms include cardiovascular event restraint, plaque development/regression inhibition, and improved plaque cell function.
- Japanese clinical trials confirmed statins' effectiveness, supporting their role in managing hyperlipidemia.
Impact:
- Findings support the broader application of statins in preventing atherosclerosis progression.
- Emphasizes the importance of understanding lipid-lowering agent mechanisms for effective hyperlipidemia treatment.
- Highlights the need for individualized treatment plans, considering patient-specific factors and combination therapies.
Abstract:
An appearance of statin did not only cause fall of onset rate and the death rate of coronary arteries disease, but also a fall of the total death rate. These results are restraint of cardiovascular event, development and regression restraint of plaque, function improvement of plaque constitution cells, resulting in the decrease of the total death. However, most of the clinical lipid intervention trial were European and USA results, and there was a difference of a quantity of dosage, too, and results in a Japanese were waited for. Results of a clinical lipid intervention trials in a Japanese appeared by degrees, too though a little too late. From those results, it is proposed that hyperlipidemia is managed whether there are several risk factors of atherosclerosis except hyperlipidemia. Needless to say, it is for the greatest purpose of hyperlipidemia treatment to prevent the development and progression of atherosclerosis. Therefore, it is necessary to treat hyperlipidemia after having fully understood the function mechanism of lipid-lowering agents and after having thought about the morbid state of a patient. In addition, on the occasion of a combination treatment it is necessary to administer it after having understood the each other's function mechanism.